Results 51 to 60 of about 8,133 (247)

Peptide Marriages: Modular Assembly of Multi‐Agonist Therapeutics

Chemistry – A European Journal, EarlyView.
A modular polyethylene glycol (PEG) scaffold enables rapid assembly of dual peptide agonists using strain‐promoted azide–alkyne cycloaddition (SPAAC) and copper‐catalysed azide–alkyne cycloaddition (CuAAC). Glucagon‐like peptide‐1 (GLP‐1) and amylin agonists were combined with controlled valency, yielding low‐picomolar activity and receptor‐selective ...
Kristina A. Kostadinova, Jan L. Venne, Sona Krajcovicova, James Dodgson, Wouter F. J. Hogendorf, Thomas E. Nielsen, David Hymel, Hannah Bolt, Andie Collinson, Jason Day, Jefferson Revell, David R. Spring   +11 more
wiley   +1 more source

Apolipoprotein A-IV: a protein intimately involved in metabolism

Journal of Lipid Research, 2015
The purpose of this review is to summarize our current understanding of the physiological roles of apoA-IV in metabolism, and to underscore the potential for apoA-IV to be a focus for new therapies aimed at the treatment of diabetes and obesity-related ...
Fei Wang, Alison B. Kohan, Chun-Min Lo, Min Liu, Philip Howles, Patrick Tso   +5 more
doaj   +1 more source

Cancer Biology and Prevention in Diabetes

Cells, 2020
The available evidence suggests a complex relationship between diabetes and cancer. Epidemiological data suggest a positive correlation, however, in certain types of cancer, a more complex picture emerges, such as in some site-specific cancers being ...
Swayam Prakash Srivastava, Julie E. Goodwin   +1 more
doaj   +1 more source

The Capacity to Secrete Insulin Is Dose-Dependent to Extremely High Glucose Concentrations: A Key Role for Adenylyl Cyclase

Metabolites, 2021
Insulin secretion is widely thought to be maximally stimulated in glucose concentrations of 16.7-to-30 mM (300-to-540 mg/dL). However, insulin secretion is seldom tested in hyperglycemia exceeding these levels despite the Guinness World Record being 147 ...
Katherine M. Gerber, Nicholas B. Whitticar, Daniel R. Rochester, Kathryn L. Corbin, William J. Koch, Craig S. Nunemaker   +5 more
doaj   +1 more source

Clinical Characterization of Enzyme and Transporter Precipitants to Evaluate Drug–Drug Interactions for Orforglipron, a Small Molecule Glucagon‐Like Peptide‐1 Receptor Agonist

Clinical Pharmacology &Therapeutics, EarlyView.
Orforglipron is an orally administered, small‐molecule glucagon‐like peptide‐1 receptor agonist in clinical development for the treatment of type 2 diabetes and obesity. Orforglipron is a substrate of CYP3A4, organic anion transporting polypeptides (OATPs) 1B/1B3, and P‐glycoprotein (P‐gp); however, precipitants commonly used to define these mechanisms
Bridget L. Morse, David E. Coutant, Xiaosu Ma, Sohini Raha, Keerthan Aithal, Clare Nicoll, Luc R. A. Rougée, Shobha Bhattachar   +7 more
wiley   +1 more source

Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease

Medicina, 2023
Metabolic-associated Fatty Liver Disease is one of the outstanding challenges in gastroenterology. The increasing incidence of the disease is undoubtedly connected with the ongoing obesity pandemic.
Aleksandra Bołdys, Łukasz Bułdak, Mateusz Maligłówka, Stanisław Surma, Bogusław Okopień   +4 more
doaj   +1 more source

Prescription Sequence Symmetry Analysis of Glucagon‐Like Peptide‐1 Receptor Agonists and Neuropsychiatric Conditions

Clinical Pharmacology &Therapeutics, EarlyView.
Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are increasingly prescribed for type 2 diabetes and weight management. However, conflicting evidence from preclinical, clinical, and pharmacovigilance studies suggests potential neuropsychiatric effects.
Maria J. Alfonso Arvez, Sam Wade, Darshna Goordeen, Jenni Ilomäki, Amanda J. Cross, Monica Langiu, George S. Q. Tan   +6 more
wiley   +1 more source

Physiology of incretins in health and disease [PDF]

, 2011
The incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), are gut peptides which are secreted by endocrine cells in the intestinal mucosa.
Deacon, Carolyn F., Ahren, Bo
core   +1 more source

Short‐term clinical responses in horses and ponies treated with canagliflozin: A clinical field study

Equine Veterinary Journal, EarlyView.
Abstract Background Treatment with the sodium‐glucose co‐transporter 2 (SGLT2) inhibitor canagliflozin in insulin dysregulated (ID) horses has shown promising results in randomised clinical trials. Larger field studies are needed to further evaluate treatment responses and potential adverse effects under real‐world conditions.
Moa Hällbom, Sanna Truelsen Lindåse, Monika Wartel, Johan Bröjer   +3 more
wiley   +1 more source

Alterations of adipokines, pancreatic hormones and incretins in acute and convalescent COVID-19 children [PDF]

, 2023
Background The Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), accountable for Coronavirus disease 2019 (COVID-19), may cause hyperglycemia and additional systemic complexity in metabolic parameters.
Ruchi Mittal, S. Lakshan Raj, Padmasani Venkat Ramanan, Nathella Pavan Kumar, K. Gowshika, Nandhini Selvaraj, Sulochana Putlibai, Anuradha Rajamanickam, Aishwarya Venkataraman, R. Sasidaran, Subash Babu, Arul Nancy Pandiarajan   +11 more
core   +1 more source